Driven by rise in demand for safe and effective medicines, along with increase in rare and chronic disorders, the plasma fractionation market is evolving steadily

Plasma fractionation is a process employed to purify and separate plasma into individual protein components. These fractionates are then purified, which can further be used as therapeutic medicines, known as plasma-derived therapies or plasma-derived medicinal products. This involves a sequence of processes, including precipitation / chromatography, purification, and virus-inactivation. Plasma fractionation is a highly developed bioprocess that can be carried out from small scale to commercial scale production. It is worth highlighting that more than 30 unique therapeutic plasma proteins have already been developed through plasma fractionation which helps to treat various indications.

The global plasma fractionation market size is estimated to grow from USD 4.80 billion in 2024 to USD 12.7 billion by 2035, representing a CAGR of 9.2% during the forecast period till 2035.

Plasma-derived therapies have lowered the healthcare expenditures that are incurred during hospitalization and have contributed to socio-economic gains. Hence, they are being increasingly adopted for treatment of a myriad of disease indications. The list of plasma-derived products along with the information on therapeutic applications have been mentioned below:

§  Albumin: Acute Respiratory Distress Syndrome, Burns, Cardiopulmonary Bypass, Hemodialysis, Hypoalbuminemia, Hypovolemia (shock), Surgery and Trauma

§  Alpha-1 Proteinase Inhibitor Therapies: Alpha-1 Antitrypsin Deficiency

§  C1 Esterase Inhibitor Therapies: Hereditary Angioedema

§  Coagulation Factors: Hemophilia A, Hemophilia B, Von Willebrand Disease and Antithrombin III Deficiency

§  Immunoglobulins: Primary Immunodeficiency Disease (PID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Idiopathic Thrombocytpenic Purpura (ITP) and Kawasaki Disease.

During our research, we identified more than 35 players that are engaged in blood plasma fractionation.

Most of the plasma fractionation facilities are located in Europe (97%). This is followed by plasma fractionation facilities located in Asia-Pacific (94%) and North America (46%). It is worth highlighting that Aegros (Israel), Grifols (Egypt) and Kamada (Israel) have plasma fractionation facilities located in the rest of the world.

97% of the plasma is fractionated to produce immunoglobulins, this is followed by albumins (94%) and coagulation factors (86%). It is worth highlighting that 30 firms are involved in fractionating blood plasma for the development of all of these aforementioned plasma-derived therapeutic products; examples of such plasma fractionation companies include (in alphabetical order, no specific selection criteria) China National Biotec Group (CNBG), Intas Pharmaceuticals, Merck KGaA, and Oryx Bio-Tech.

Majority (74%) of the plasma fractionators are large companies. This can be attributed to their extensive plasma fractionation facilities and their ability to establish a strong presence in multiple key locations, enabling them to effectively meet the growing demand. Notable examples of such plasma fractionation companies include (in alphabetical order, no specific selection criteria) ADMA Biologics, Biotest, GC Biopharma, and Hualan Biological. Additionally, we came across 6% small players with less than 50 employees; namely (in alphabetical order) CAF-DCF and Evolve Biologics.

Research Methodology

Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Plasma Fractionation Market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/plasma-fractionation-market.html 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.                       

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide. 

Contact:

Roots Analysis

+1 (415) 800 3415

[email protected]